Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type Journal Article
PMID (30712867)
Authors Yin C, Zhu B, Zhang T, Liu T, Chen S, Liu Y, Li X, Miao X, Li S, Mi X, Zhang J, Li L, Wei G, Xu ZX, Gao X, Huang C, Wei Z, Goding CR, Wang P, Deng X, Cui R
Title Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.
Journal Vol Issue Date Pages Journal Short Title
Cell 176 5 2019 Feb 21 1113-1127.e16 Cell
URL
Abstract Text Activating mutations in NRAS account for 20%-30% of melanoma, but despite decades of research and in contrast to BRAF, no effective anti-NRAS therapies have been forthcoming. Here, we identify a previously uncharacterized serine/threonine kinase STK19 as a novel NRAS activator. STK19 phosphorylates NRAS to enhance its binding to its downstream effectors and promotes oncogenic NRAS-mediated melanocyte malignant transformation. A recurrent D89N substitution in STK19 whose alterations were identified in 25% of human melanomas represents a gain-of-function mutation that interacts better with NRAS to enhance melanocyte transformation. STK19D89N knockin leads to skin hyperpigmentation and promotes NRASQ61R-driven melanomagenesis in vivo. Finally, we developed ZT-12-037-01 (1a) as a specific STK19-targeted inhibitor and showed that it effectively blocks oncogenic NRAS-driven melanocyte malignant transformation and melanoma growth in vitro and in vivo. Together, our findings provide a new and viable therapeutic strategy for melanomas harboring NRAS mutations.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
ZT-12-037-01 ZT-12-037-01 2 0
Drug Name Trade Name Synonyms Drug Classes Drug Description
ZT-12-037-01 EX-A3169 ZT-12-037-01 is an ATP-competitive small molecule inhibitor, which inhibits the kinase activity of STK19, potentially resulting in increased apoptosis and reduced tumor growth (PMID: 30712867).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
NRAS S89A missense loss of function NRAS S89A does not lie within any known functional domains of the Nras protein (UniProt.org). S89A demonstrates loss of both Nras phosphorylation and activation of downstream signaling as compared to wild-type Nras in cell culture (PMID: 30712867).
NRAS S89D missense unknown NRAS S89D does not lie within any known functional domains of the Nras protein (UniProt.org). S89D results in cell proliferation, colony formation and activation of Nras signaling similar to wild-type Nras in culture, but results in increased NRAS signaling and colony formation when combined with NRAS Q61R (PMID: 30712867), and therefore, its effect on Nras protein function is unknown.
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
NRAS Q61R melanoma sensitive ZT-12-037-01 Preclinical - Cell line xenograft Actionable In a preclinical study, ZT-12-037-01 treatment induced apoptosis and inhibited cell proliferation and colony formation in culture and reduced tumor growth and increased survival in cell line xenograft models of melanoma harboring NRAS Q61R (PMID: 30712867). 30712867
BRAF V600E melanoma decreased response ZT-12-037-01 Preclinical - Cell culture Actionable In a preclinical study, melanoma cell lines harboring BRAF V600E demonstrated reduced inhibition of cell proliferation and induction of apoptosis compared to cells harboring NRAS Q61R in culture when treated with ZT-12-037-01 (PMID: 30712867). 30712867